LXRX - Lexicon Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$6.00
DETAILS
HIGH:
$6.00
LOW:
$6.00
MEDIAN:
$6.00
CONSENSUS:
$6.00
UPSIDE:
164.32%
About Lexicon Pharmaceuticals, Inc. (https://www.lexpharma.com)
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Michael Exton | Chief Executive Officer & Director | 1970 | $1,149,418 USD |
| Craig Granowitz | Senior Vice President & Chief Medical Officer | 1965 | $789,535 USD |
| Brian T. Crum | Senior Vice President, General Counsel & Secretary | 1973 | $687,366 USD |
| Scott Coiante | Senior Vice President & Chief Financial Officer | 1967 | $646,287 USD |
| Wendy E. McDermott | Senior Vice President of Human Resources | 1971 | $580,446 USD |
| Kristen L. Alexander | Vice President of Finance & Accounting | 1968 | $379,807 USD |
| Lisa DeFrancesco | Senior Vice President of Investor Relations & Corporate Communications | 1980 | – |
| Rachel Yap Martens | Senior VP of Partnerships & Corporate Strategy | 1984 | – |
| Suma Gopinathan | Senior Vice President of Discovery | 1973 | – |